A new and more compelling strategy must be crafted to engage critics on drug pricing and bolster biopharmaceuticals as a leader in technological innovations that lower health costs overall. William Looney reports.

A closer look at this year's Industry Audit numbers hints to a clear divide between two alternative strategies for long-term growth: scale versus focus. William Looney comments.

The big data revolution offers great promise for drug development versus the traditional ways of bringing medicines to market, but there is a larger issue at stake: how to turn data quantity into data quality. William Looney reports.

Amid the release Pharm Exec's Emerging Pharma Leaders 2015, William Looney considers what will determine true leadership in big Pharma in the years ahead.

Institutionalizing the teachable moment with GENiE, a new network focused on advancing the idea that for healthcare to change, the education of its leaders must change first.

This year's Pharm Exec Brand of the Year is a huge game-changers, but the big-picture impact will come down to pricing, distribution, and the broader goal of making sure that those patients who need the cure, get the cure, writes William Looney.

Learnings gleaned from our annual EAB meeting, hosted this year by Dr. David Nash, Dean of the Thomas Jefferson University School of Population Health.

Pharma jumps on board personal genomics train—at least for test drive—but will journey ultimately help transform treatment or stall out as just another fad?

South Africa may have the most developed market for biopharmaceuticals on the African continent, but there are a few critical shortcomings, writes William Looney.

The small biotech space—credited with ending the drought in new FDA drug approvals in recent years—takes center stage at this year's J.P. Morgan Investors Conference.